Abstract:Background: Infantile hemangiomas (IHs) are the most common benign vascular tumor of infancy. They occur more frequently in female infants. The cause of hemangioma is currently unknown; however, current studies suggested the importance of estrogen (E2) signaling in hemangioma proliferation.Methods: Hemangioma-derived stem cells (HemSCs) were cultured with estrogen for 48-72 h; the cell viability and proliferation were evaluated with the messenger RNA (mRNA) and protein expression levels of fibroblast growth factor 2 (FGF2), vascular endothelial growth factor-A (VEGF-A) and estrogen receptor-alpha (ER-alpha), by application of several in vitro assays, such as methyl thiazolyl tetrazolium (MTT), reverse transcriptase-polymerase chain reaction (RT-PCR), real-time PCR, enzyme-linked immunosorbent assay (ELISA) and Western blotting. Also, the cell population's response to external estrogen was investigated by in vivo experiments. HemSCs and human umbilical vein endothelial cells (HUVECs) were mixed and injected subcutaneously into 20 flank of BALB/ c-nu mice, which were randomly divided into 5 groups based on different E2 treatment doses (0, 0.01, 0.1 and 1 mg, respectively), 0.1 mg dimethyl sulfoxide (DMSO) as control. Each group of mice were treated intramuscularly every week, then 2 and 4 weeks later, the subcutaneous implants were harvested and evaluated the tumor tissues with microvessel density (MVD) assay and immunohistochemistry.Results: The study demonstrated that application of E2 increased the expression of FGF2, VEGF-A, and ER-alpha in HemSCs with the optimal concentration from 10(-9) to 10(-5) M. Two-week treatment of E2 promoted expression of VEGF-A and FGF2 in HemSCs culture. Morphological, histological and immunohistological improvements were observed in vivo using murine IH model in which HemSCs and HUVECs were implanted into BALB/c-nu mice that were post-injected with E2. In the grafts, mean MVD was markedly increased.Conclusion: The results suggested that E2 promotes angiogenesis via combination with ER-alpha to up-regulate the expression of VEGF-A in HemSCs, promoting proliferation of IHs. These findings provide critical insight into the potential mechanisms of E2 action on IHs.

CD146+ mural cells from infantile hemangioma display proangiogenic ability and adipogenesis potential in vitro and in xenograft models

CD133 Selected Stem Cells from Proliferating Infantile Hemangioma and Establishment of an in Vivo Mice Model of Hemangioma

Differentiation and Pro-Angiogenic Potential of Infantile Hemangioma Stem Cells

Three-Dimensional Microtumor Formation of Infantile Hemangioma-Derived Endothelial Cells for Mechanistic Exploration and Drug Screening

PDGFR-β (+) Perivascular Cells from Infantile Hemangioma Display the Features of Mesenchymal Stem Cells and Show Stronger Adipogenic Potential in Vitro and in Vivo.

Apelin Receptor Can Act As a Specific Marker and Promising Therapeutic Target for Infantile Hemangioma

Macrophages Contribute to the Progression of Infantile Hemangioma by Regulating the Proliferation and Differentiation of Hemangioma Stem Cells.

Cell Fate Regulation During the Development of Infantile Hemangioma

Role Of Endothelial-Mesenchymal Transition In The Tumorigenesis Of Infantile Hemangioma

Mast cell in infantile hemangioma

The role of multipotential stem cells in human infantile hemangioma

Estrogen-Mediated Hemangioma-Derived Stem Cells Through Estrogen Receptor-Alpha For Infantile Hemangioma

Biology of Infantile Hemangioma

Infantile hemangioma models: is the needle in a haystack?

Signaling pathways in the development of infantile hemangioma

The Preliminary Study of Hemangioma Model Constructed by Using Immortalized Human Umbilical Vein Endothelial Cells

JAGGED1 Signaling Regulates Hemangioma Stem Cell–to–Pericyte/Vascular Smooth Muscle Cell Differentiation

Human Monocyte-Derived Hemangioma-Like Endothelial Cells: Evidence from an in Vitro Study

Stem cell in infantile hemangioma

Insights into the mechanisms of angiogenesis in infantile hemangioma

Serum Apelin As a Potential Biomarker for Infantile Hemangiomas.